Johnson & Johnson Jumps 11.8% on Europe Ablation Expansion as S&P 500 Slips 0.4%
Updated
Updated · Trefis · Jun 30
Johnson & Johnson Jumps 11.8% on Europe Ablation Expansion as S&P 500 Slips 0.4%
1 articles · Updated · Trefis · Jun 30
Summary
Johnson & Johnson rose 11.8% over the past week, outperforming a 0.4% drop in the S&P 500 as investors reacted to its European cardiac ablation expansion.
Five-year correlation of 0.18 with the S&P 500 suggests JNJ has moved largely on company-specific drivers rather than broader market swings.
Over the past year, JNJ captured about 26% of the market’s up days and only 51% of its down days, reinforcing its role as a partial portfolio shock absorber.
Management is pitching a stronger growth case—citing its Innovative Medicine pipeline, double-digit ex-STELARA growth and ICOTYDE’s launch potential—while analysts still question execution and whether consensus fully reflects that outlook.
The next key test is early ICOTYDE adoption, which could show whether JNJ’s recent surge marks durable business momentum rather than a short-term stock move.